Get started
Author

Caroline Phillips

Observed names: C Phillips, C. Phillips, Phillips, Caroline
OpenAlex ID: A5108257450
Pharmacological Characterization of AZD5069, a Slowly Reversible CXC Chemokine Receptor 2 Antagonist
2015 · David J. Nicholls, Katherine Wiley, et al. · Journal of Pharmacology and Experimental Therapeutics · 93
The Wnt Pathway Inhibitor RXC004 Blocks Tumor Growth and Reverses Immune Evasion in Wnt Ligand–dependent Cancer Models
2022 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research Communications · 40
Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition
2022 · Dustin J. Flanagan, Simon A. Woodcock, et al. · Pharmacology & Therapeutics · 36
PDF
Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists
2015 · Rupert P. Austin, Colin Bennion, et al. · Bioorganic & Medicinal Chemistry Letters · 19
Lead optimisation of pyrazoles as novel FPR1 antagonists
2011 · Andrew D. Morley, Sarah King, et al. · Bioorganic & Medicinal Chemistry Letters · 18
Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs
2021 · Sarah Brumskill, Lawrence N. Barrera, et al. · Journal of Physiology and Biochemistry · 16
PDF
517MO Phase I study of the porcupine (PORCN) inhibitor RXC004 in patients with advanced solid tumours
2021 · N. Cook, S. Blagden, et al. · Annals of Oncology · 11
Abstract 506: Wnt/â-Catenin pathway inhibitor RXC004 enhances the immunity of pre-clinical models of cancer
2019 · Caroline Phillips, Inder Bhamra, et al. · Cancer Research · 11
Novel porcupine (PORCN) inhibitor RXC004: Evaluation in models of RNF43 loss of function cancers.
2017 · Inder Bhamra, Nick Adams, et al. · Journal of Clinical Oncology · 10
A multi-arm, phase 2, open-label study to assess the efficacy of RXC004 as monotherapy and in combination with nivolumab in patients with ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable colorectal cancer following standard treatments.
2022 · Scott Kopetz, Van K. Morris, et al. · Journal of Clinical Oncology · 9
Abstract 3764: Porcupine inhibitor RXC004 enhances immune response in pre-clinical models of cancer
2018 · Inder Bhamra, Richard Armer, et al. · Cancer Research · 9
Preclinical data using a novel porcupine inhibitor demonstrates that inhibition of porcupine is a promising target for the treatment of Idiopathic Pulmonary Fibrosis
2019 · Peter Bunyard, Inder Bhamra, et al. · European Respiratory Journal · 5
Abstract 3874: Efficacy of the Wnt/Beta-Catenin pathway inhibitor RXC004 in genetically-defined models of cancer
2019 · Simon Woodcock, Inder Bhamra, et al. · Cancer Research · 5
Abstract 5160: Development of REDX05358, a novel highly selective and potent pan RAF inhibitor and a potential therapeutic for BRAF and RAS mutant tumors
2017 · Helen Mason, Simon Scrace, et al. · Cancer Research · 4
REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK
2016 · Nicolas E. S. Guisot, Stuart A. Best, et al. · Blood · 4
Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors
2024 · Natalie Cook, Sarah Blagden, et al. · Cancer Research · 3
391P Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
2024 · J.A. Bridgewater, L. Chantrill, et al. · Annals of Oncology · 2
Abstract 2566: Pre-clinical efficacy of the Wnt pathway inhibitor RXC004 in combination with anti-cancer therapies
2022 · James Kelly, Simon Woodcock, et al. · Cancer Research · 2
Abstract 2677: JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in RAF and RAS mutant tumor pre-clinical models
2022 · Robert Hauptschein, Simon Woodcock, et al. · Cancer Research · 2
Abstract 998: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer
2021 · Caroline Phillips, Simon Woodcock, et al. · Cancer Research · 2
P016 GI restricted ROCK inhibitors show potential to treat fibrosis and stenosis associated with inflammatory bowel disease
2018 · C Jones, P Bunyard, et al. · Journal of Crohn s and Colitis · 2
Abstract 720: Combining zelasudil, a small molecule ROCK2 inhibitor, with chemotherapy or immunotherapy improves response in preclinical models of pancreatic cancer
2024 · Marina Pajic, Benjamin McLean, et al. · Cancer Research · 1
222P Therapeutic opportunities for porcupine inhibition in gastrointestinal cancer
2023 · N. Cook, S. Wu, et al. · Annals of Oncology · 1
PDF
Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening
2017 · M. Bingham, I. Bhamra, et al. · Annals of Oncology · 1
PDF
Novel Porcupine inhibitor RXC004: Potent efficacy in animal models of cancer through direct tumour targeting and immunomodulatory mechanisms
2016 · I. Bhamra, V. Abet, et al. · European Journal of Cancer · 1
Works count: 32
Citation count: 307
H-index: 9
I10-index: 9
Year
Topic
Type